Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Quest Clinical Research
mi
from
San Francisco, CA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Quest Clinical Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL
mi
from
Pensacola, FL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL
mi
from
Pensacola, FL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Iowa Departments of Internal Medicine and Microbiology University of Iowa
mi
from
Iowa City, IA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Iowa Departments of Internal Medicine and Microbiology University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Pennsylvania Clinical Trials Unit
mi
from
Philadelphia, PA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Pennsylvania Clinical Trials Unit
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Clinical Research Puerto Rico
mi
from
San Juan,
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Clinical Research Puerto Rico
mi
from
San Juan,
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Dupont Circle Physician's Group
mi
from
Washington, D.C.,
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Dupont Circle Physician's Group
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers
Status: Enrolling
Updated:  7/20/2017
Clinical Research Facility
mi
from
Lenexa, KA
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers
Status: Enrolling
Updated: 7/20/2017
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Mayo Clinic Arizona /ID# 90539
mi
from
Phoenix, AZ
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Mayo Clinic Arizona /ID# 90539
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
University of California, San Francisco /ID# 90538
mi
from
San Francisco, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
University of California, San Francisco /ID# 90538
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
University of Colorado Cancer Center /ID# 90535
mi
from
Aurora, CO
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
University of Colorado Cancer Center /ID# 90535
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Northwestern University /ID# 90562
mi
from
Chicago, IL
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Northwestern University /ID# 90562
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
The University of Chicago Medical Center /ID# 90563
mi
from
Chicago, IL
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
The University of Chicago Medical Center /ID# 90563
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Indiana University /ID# 90536
mi
from
Indianapolis, IN
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Indiana University /ID# 90536
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Lahey Clinic Hospital and Medical Center /ID# 100055
mi
from
Burlington, MA
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Lahey Clinic Hospital and Medical Center /ID# 100055
mi
from
Burlington, MA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Henry Ford Health System /ID# 125419
mi
from
Detroit, MI
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Henry Ford Health System /ID# 125419
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Columbia University Medical Center /ID# 90533
mi
from
New York, NY
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Columbia University Medical Center /ID# 90533
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
The Liver Institute at Methodist Dallas Medical Ctr /ID# 90537
mi
from
Dallas, TX
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
The Liver Institute at Methodist Dallas Medical Ctr /ID# 90537
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Baylor University Medical Center /ID# 96250
mi
from
Dallas, TX
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Baylor University Medical Center /ID# 96250
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated:  7/28/2017
Royal Prince Alfred Hospital /ID# 123975
mi
from
Camperdown,
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
Status: Enrolling
Updated: 7/28/2017
Royal Prince Alfred Hospital /ID# 123975
mi
from
Camperdown,
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Carmichael, CA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Carmichael, CA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Davis, CA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Davis, CA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Riverside, CA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Sacramento, CA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Fort Wayne, IN
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Indianapolis, IN
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Boston, MA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
New York, NY
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Stony Brook, NY
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Tulsa, OK
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Portland, OR
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Houston, TX
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Seattle, WA
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
The Bronx, NY
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Status: Enrolling
Updated:  8/3/2017
NYU Medical Center
mi
from
New York, NY
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Status: Enrolling
Updated: 8/3/2017
NYU Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Examining the Immunological Process of Autoimmune Patients
Examining the Immunological Process of Autoimmune Patients
Status: Enrolling
Updated:  8/7/2017
University of Florida
mi
from
Gainesville, FL
Examining the Immunological Process of Autoimmune Patients
Examining the Immunological Process of Autoimmune Patients
Status: Enrolling
Updated: 8/7/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
University of Miami / Cedars Medical Center
mi
from
Miami, FL
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
University of Miami / Cedars Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
St. Joseph's Hospital
mi
from
Atlanta, GA
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
St. Joseph's Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Southern Illinois University
mi
from
Springfield, IL
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
North Memorial Medical Center
mi
from
Robbinsdale, MN
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
North Memorial Medical Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Bamberg County Hospital
mi
from
Bamberg, SC
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Bamberg County Hospital
mi
from
Bamberg, SC
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Baptist Medical Center
mi
from
San Antonio, TX
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Baptist Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Comparative Effectiveness of Antibiotics for Respiratory Infections
Comparative Effectiveness of Broad vs. Narrow Spectrum Antibiotics for Acute Respiratory Tract Infections in Children
Status: Enrolling
Updated:  8/11/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Comparative Effectiveness of Antibiotics for Respiratory Infections
Comparative Effectiveness of Broad vs. Narrow Spectrum Antibiotics for Acute Respiratory Tract Infections in Children
Status: Enrolling
Updated: 8/11/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Status: Enrolling
Updated:  8/14/2017
GSK Investigational Site
mi
from
Birmingham, AL
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Status: Enrolling
Updated: 8/14/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Status: Enrolling
Updated:  8/14/2017
GSK Investigational Site
mi
from
Tucson, AZ
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Status: Enrolling
Updated: 8/14/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials